INTRODUCTION: Alterations in the lipidic metabolism are common in patients with cancer. Medicinal fungus may show hypolipidemic activity. OBJECTIVE: To evaluate the effects of dietary supplementation with Agaricus sylvaticus fungus in lipidic profile of patients with colorectal cancer in post-surgery phase. MEHTODS: Randomized, double-blind, placebo-controlled clinical trial carried out at the Federal District Base Hospital, for six months. Samples of 56 enrolled patients, stadiums phase I, II and III, divided in two groups: placebo group and group supplemented with Agaricus sylvaticus (30mg/kg/day). Results were analyzed with Microsoft Excel 2003 and SPSS 14.0 programs, with p = 0.05. RESULTS: The Agaricus sylvaticus group had initial total cholesterol levels of 207.36±52.67mg/dL, low-density lipoprotein of 120.79±44.02mg/dL and triglycerides of 181.64±187.52mg/dL. After six months of supplementation it was observed a reduction 191.11±39.72mg/dL (p = 0.01), 103.08±39.20mg/dL (p = 0.0001) and 168.04±146.91mg/dL (p = 0.18), respectively. In the placebo group it was observed not-significant increase of total cholesterol levels (p = 0.08) and significant increase of low-density lipoprotein (p = 0.01) and triglycerides (p = 0.0001). No significant statistically alterations were observed in the levels of high-density lipoprotein and very-low-density lipoprotein in both groups. CONCLUSION: Results suggest that the dietary supplementation with Agaricus sylvaticus may significantly improve the lipidic profile of colorectal cancer patients in post-surgery phase.
Agaricus sylvaticus; medicinal fungus; metabolic alterations; lipidic metabolism; colorectal cancer
